Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
SMI increment appeared as a favorable predictor for these uHCC patients who received TACE-MTAs-ICIs therapy.
Authors
- Wen Chen (ORCID: https://orcid.org/0000-0002-6603-0056)
- Qing‐Quan Zu (ORCID: https://orcid.org/0000-0001-7359-0791)
- Ye Ding (ORCID: https://orcid.org/0000-0002-7732-3073)
- Hai‐Bin Shi (ORCID: https://orcid.org/0000-0003-1293-5789)
- Sheng Liu (ORCID: https://orcid.org/0000-0002-4058-4413)
- Jin Liu (ORCID: https://orcid.org/0000-0002-0557-026X)
- Jin-Xing Zhang (ORCID: https://orcid.org/0000-0003-1561-100X)
- Hai‐Tao Yan
- Xiao Shen
Institutions
- Nanjing Maternity and Child Health Care Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/jhc.s506412
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nanjing Medical University